Clinical Trial Update: A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating adverse events of intravenous Etentamig (ABBV-383) in adults with relapsed or refractory multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Etentamig

Snippet

Sponsor: AbbVie | Conditions: Multiple Myeloma | Phase 1 | Status: RECRUITING